[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Synthomer Plc LSE:SYNT London Ordinary Share GB0009887422 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -8.50 -1.62% 516.00 765,652 16:35:07
Bid Price Offer Price High Price Low Price Open Price
515.00 516.00 522.00 512.50 522.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 1,644.20 20.30 0.70 737.1 2,192
Last Trade Time Trade Type Trade Size Trade Price Currency
17:25:59 O 23 516.00 GBX

Synthomer (SYNT) Latest News

More Synthomer News
Synthomer Investors    Synthomer Takeover Rumours

Synthomer (SYNT) Discussions and Chat

Synthomer Forums and Chat

Date Time Title Posts
07/9/202115:29Synthomer509
07/8/201819:23Synthomer (SYNT) One to Watch on Monday 1

Add a New Thread

Synthomer (SYNT) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Synthomer trades in real-time

Synthomer (SYNT) Top Chat Posts

DateSubject
26/9/2021
09:20
Synthomer Daily Update: Synthomer Plc is listed in the Chemicals sector of the London Stock Exchange with ticker SYNT. The last closing price for Synthomer was 524.50p.
Synthomer Plc has a 4 week average price of 490.60p and a 12 week average price of 486.40p.
The 1 year high share price is 570.50p while the 1 year low share price is currently 302.80p.
There are currently 424,850,961 shares in issue and the average daily traded volume is 816,591 shares. The market capitalisation of Synthomer Plc is £2,192,230,958.76.
23/8/2021
11:15
philanderer: UBS RAISES SYNTHOMER PRICE TARGET TO 550 (530) PENCE - 'NEUTRAL'
06/8/2021
18:15
philanderer: (Sharecast News) - London's FTSE 250 was down 0.2% at 23,468.78 in afternoon trade on Friday. Synthomer was knocked lower by a downgrade to 'hold' from 'buy' at Berenberg. The bank said that while welcome, Synthomer's pre-released first-half results probably mark the end of the organic upgrade cycle. "For all management's work in upgrading the portfolio and reducing leverage, the stock appears to be entering a precarious phase for industrial names: increasing amounts of capex directed towards a level at which there is declining return on capital employed (nitrile latex). "Given two-year valuation is no longer low enough to make a compelling case for shares, we downgrade to hold with a new price target of 550p."
06/8/2021
09:49
philanderer: Downgrade it is then.. BERENBERG CUTS SYNTHOMER TO 'HOLD' (BUY) - PRICE TARGET 550 (560) PENCE
05/8/2021
19:15
philanderer: Canaccord put out a 'buy', tp 750p , on monday this week. ---------------- Canaccord ups price target on Synthomer Analysts at Canaccord Genuity raised their target price on chemicals outfit Synthomer from 700.0p to 750.0p on Monday, citing a fourth upgrade to full-year guidance. Synthomer announced a further update to its guidance for 2021 underlying earnings in July, EBITDA, now to "above £500.0m" from previous estimates of over £450.0m. The Canadian bank pointed out that the source of the further upgrade appeared to be broad-based. "Overall, we now expect net EPS to be up more than 150% this year on unit margins (€/ton) roughly doubling, with the overwhelming majority of that improvement coming from the nitrile business," said Canaccord. "Whilst normalisation is likely to come in the medium term, we continue to see super-normal profits in nitrile through 2022E, due both to the direct and ongoing impacts of the pandemic on PPE demand, but also the indirect increase in healthcare workers' (and others') demand for greater protection." As a result, Canaccord, which also stood by its 'buy' rating on the stock, upgraded 2022/23 EPS estimates by roughly 8% but also highlighted "increased optionality" at Synthomer, whether from the rapid debt reduction or opportunity for further expansion. [...]
20/7/2021
10:49
philanderer: JEFFERIES RAISES SYNTHOMER PRICE TARGET TO 715 (650) PENCE - 'BUY'
14/7/2021
14:03
philanderer: UBS RAISES SYNTHOMER PRICE TARGET TO 530 (520) PENCE - 'NEUTRAL'
12/7/2021
16:43
philanderer: Peel Hunt upgrades Synthomer Peel Hunt has upgraded chemicals business Synthomer (SYNT) as momentum builds in its end markets and M&A potential arises. Analyst Jolyon Wellington upgraded his recommendation from ‘add’ to ‘buy’ and increased the target price from 538p to 600p on the stock, which closed up 3.6%, or 18p, at 521p on Friday. ‘Synthomer’s end markets appear to be continuing strong momentum, and we believe upgrades to financial year 2022 [guidance] are possible at the forthcoming interims,’ he said. ‘With strong cashflow generation paying down debt, and new chief executive Michael Willome confirmed, M&A is back on the cards.’ He added the combination of Willome, an M&A specialist, and a ‘replenished balance sheet’ means the group could spend up to £1bn on acquisitions. HTTPS://citywire.co.uk/wealth-manager/news/share-tips-thg-st-modwen-bunzl-mj-gleeson-and-synthomer/a1529614#i=6
09/7/2021
08:32
tomps2: Richard Leonard mentions Synthoma (SYNT) in the latest PIWORLD Interview at 17m20s. Watch the video here: Https://www.piworld.co.uk/education-videos/a-piworld-interview-richard-leonard-what-hes-been-buying-july-2021/ Or listen to the podcast here: Https://piworld.podbean.com/e/a-piworld-interview-richard-leonard-what-he-s-been-buying-july-2021/
25/6/2021
08:39
tomps2: Daniel Jones ‘slams’ Synthomer (SYNT) in the latest PIWORLD/Stockopedia StockSlam at 1h04m40s Watch the video here: Https://www.piworld.co.uk/education-videos/the-stockopedia-piworld-virtual-stockslam-june-2021/ Or listen to the podcast here: Https://piworld.podbean.com/e/the-stockopediapiworld-virtual-stockslam-june-2021/
15/9/2019
09:21
robow: GREAT IDEAS 10 | SHARES | 12 September 2019 Chemicals firm Synthomer (SYNT) looks very tempting at the current price following a big sell-off over the past year. The firm’s share price dropped from around 530p a year ago to 280p last month and saw the stock trade on nearly its lowest rating in a decade, while its level of debt compared to how much it’s earning is expected to double. But with the business on the cusp of global expansion as it aims to keep up with soaring demand for its products, investors with a long-term view may want to take advantage of the firm’s cheap valuation. The chemicals sector has historically been a good place to invest with significant share price gains over the past decade and occasionally generous dividends. But chemicals companies have been caught up by concerns over a global economic slowdown in the past year, and some in the market think this may feed into weaker demand for chemicals products. Synthomer has tried to expand significantly to keep up with demand for its speciality products, sought after due to many factors such as urbanisation, ageing demographics and stricter legislation. The firm supplies aqueous polymers to companies, which The company should benefit from capacity expansion and a deal to boost its position in the US and Europe The outlook is looking brighter for Synthomer Synthomer is also forecast by analysts at Canaccord and Numis to have a much stronger second half of this year as market conditions are set to improve. That combined with its completed upgrades to facilities in Germany and Malaysia means the firm will have greater capacity to meet demand for its products. Its net debt-to-earnings ratio is expected to increase next year to between 2.2 and 3-times as the Omnova deal is completed. But Synthomer has a clear plan to get this down below 2-times by the end of 2021. Its management team has a disciplined approach to M&A, with a ‘conservative capital’ policy meaning it’s unlikely to ever be reckless in the pursuit of growth. help create new products and boost the performance of existing ones, such as footwear insoles, condoms, packaging tapes, carpets and waterproofing products. While strong on the consumer side, investors had questioned Synthomer’s growth prospects given its lack of real penetration into the industrial market. But the proposed deal to acquire Omnova Solutions, an American speciality chemicals business operating in sectors like construction and oil and gas, could make the market reappraise Synthomer. As well as the US, Omnova has manufacturing and technical facilities in Europe, Thailand and China. Analysts at UBS believe the acquisition will help Synthomer sell more products in the US, and help it expand its facilities in Europe. SYNT is also forecast by analysts at Canaccord and Numis to have a much stronger second half of this year as market conditions are set to improve. That combined with its completed upgrades to facilities in Germany and Malaysia means the firm will have greater capacity to meet demand for its products. Its net debt-to-earnings ratio is expected to increase next year to between 2.2 and 3-times as the Omnova deal is completed. But Synthomer has a clear plan to get this down below 2-times by the end of 2021. Its management team has a disciplined approach to M&A, with a ‘conservative capital’ policy meaning it’s unlikely to ever be reckless in the pursuit of growth. help create new products
Synthomer share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
SYNT
Synthomer
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210926 16:46:39